
Politicians from across the political spectrum are up in arms over healthcare giant Sanofi’s plans to sell France’s best-known medical drug Doliprane to US investors, a move critics say would lead to a “loss of sovereignty” for the country in a sensitive industry.
Trending
- ‘Wetenschappers met belangen in afslankindustrie beïnvloeden obesitasdebat’
- Leeds maternity inquiry must include care culture, says father
- FIFA unveils new Peace Prize ahead of 2026 World Cup draw in Washington
- Bayern Munich’s perfect start makes football history – DW – 11/05/2025
- What does Bihar election mean for Modi’s BJP? – DW – 11/06/2025
- 'Health is the face of climate change': how can cities mitigate the impact of global warming
- UK interest rates set to stay at 4%, but policymakers ‘deeply divided’
- Philippines declares emergency as Kalmaegi death toll soars – DW – 11/06/2025
